Ipca to market NovaLead’s patented, repurposed drug Diulcus® for the treatment of Diabetic Foot Ulcer (DFU)
The approval is based on Phase III study which established that NovaLead’s patented drug branded as Diulcus®, which will be marketed in India by Ipca. Diulcus® promotes the complete closure of DFU significantly better than Standard of Care, which is the present treatment of choice. Currently there is a global unmet medical need for the treatment of DFU.